Some retrospective studies on melanoma [364] and non-small cell lung cancer (NSCLC) [366] in which either anti-PD-1 or anti-PD-L1 was administered showed little difference in overall survival (OS), progression-free survival (PFS) or toxicity between age groups. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.